0Suppliers
3Customers
2Debt Items
11Related Chains

Aurinia Pharmaceuticals Inc. Suppliers

No suppliers on recordAurinia Pharmaceuticals Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Aurinia Pharmaceuticals Inc. Customers

TickerNameConfidenceEvidence
OTSUKA OTSUKA 95% In August 2022, the Company entered into a commercial supply agreement with Otsuka to: (i) supply LUPKYNIS inventory to Otsuka at cost plus a margin; and (ii) provide manufacturing and other services…
OTSUKA-PHARMACEUTICAL-CO-LTD OTSUKA-PHARMACEUTICAL-CO-LTD 95% Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), for the European and Japanese market.
VERA Vera Therapeutics, Inc. 72% Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or …

Aurinia Pharmaceuticals Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
AUPH-DEBT Debt stack $68.6M 90% Market cache reports total debt of $68.6M.
AUPH-DEBT-7974 Warrants outstanding: 0 90% xbrl warrant detail from xbrl 2022-12-31.

Aurinia Pharmaceuticals Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Aurinia Pharmaceuticals Inc..

Aurinia Pharmaceuticals Inc. Ownership

HolderNameConfidenceEvidence
AUPH-OWNER-TANG-CAPITAL-MANAGEMENT-LLC TANG CAPITAL MANAGEMENT LLC 90% 13F overlay lists TANG CAPITAL MANAGEMENT LLC as top holder; 261 tracked holders.

Aurinia Pharmaceuticals Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CLYM Climb Bio, Inc. 100.00 2
JBIO Jade Biosciences, Inc. 100.00 2
TVTX Travere Therapeutics, Inc. 100.00 2
SNYNF Sanofi 100.00 2
OTSUKA OTSUKA 65.55 1 ['receiving']
ATAI AtaiBeckley Inc. 50.00 2
KZR Kezar Life Sciences, Inc. 38.88 1 ['receiving']
VERA Vera Therapeutics, Inc. 36.29 1 ['customer']
ENODIA ENODIA 24.13 2
PARENT PARENT 18.25 2
NVSEF Novartis AG 14.78 2